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cell types, allows precise understanding of genetic and epigenetic aber-
rations. Indeed, this approach has vastly improved cancer management
for numerous cancer types. For instance, patients of breast cancer are
beneﬁtted by different management schemes according to distinct
breast cancer subtypes (i.e. luminal A, luminal B, HER2 and basal-like).
It is widely accepted that the feasibility of personalized medicine
battling cancer is laid by exploiting the complete malignant/driver
events within a particular cancer subtype. However, the direction of
cancer research is tilted recently by a suggestion that cancer manage-
ment can be improved by bringing out a bigger picture of the cancer
population. Here, the idea of pan-cancer analysis is raised by The Cancer
Genome Atlas (TCGA) program in which different cancer types are
gathered together for analysis, as it is believed that diverging driver
events among various cancer types most often generate converging
genetic signatures and biological pathways during cancer development.
The pan-cancer analysis project builds a joint data set from separate
TCGA disease projects of multiple cancer types, which increases the
statistical power to detect functional genomic determinants of disease.
Subsequently, it allows the identiﬁcation of both tissue-speciﬁc aspects
of cancer and intrinsic molecular commonalities across tumor types
(Cancer Genome Atlas Research Network et al., 2013). With this ap-
proach, several groups have already identiﬁed critical oncogenic signa-
tures (Ciriello et al., 2013), mutation landscape (Kandoth et al., 2013)
and microRNA-target interactions (Jacobsen et al., 2013) across diverse
cancer types. In this issue of EBioMedicine, Ching et al. utilize the pan-
cancer analysis to explore the diagnostic and prognostic potentials of
long non-coding RNAs (lncRNAs), and subsequently reveal a panel of
six lncRNAs as biomarkers formultiple cancer types (Ching et al., 2016).DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2016.03.023.
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compared to mRNAs (Derrien et al., 2012). The work of Ching et al.
supported this notion, and extended it by showing a reduction of
speciﬁcity after malignant transformation, which is consistent with
the de-differentiation status of cancers widely observed. They further
show that lncRNA proﬁles in cancer cells are highly speciﬁc to distinct
cancer types, which pinpoint the predicting values of lncRNA expres-
sions during cancer management. Numerous studies have demonstrat-
ed the potential of different lncRNAs for cancer diagnosis and prognosis,
but the investigations are mainly focusing on a single cancer subtypes.
Ching et al. take a global approach and identify six pan-cancer lncRNAs
that robustly and accurately predict a wide range of cancer types. The
six pan-cancer lncRNAs are also meritorious in predicting overall sur-
vival and relapse free survival in different cancer types. This ﬁnding
should have laid the foundation for the development of biomarker
screening platform for non-invasive testing of cancer incidence and out-
come. More importantly, the pan-cancer analysis approach makes the
translation of the ﬁndingmore convenient, and shortens the timeframe
of clinical trials because of the availability of a larger pool of patients.
This may be an important step towards a more practical health-
checking module in the future. On the other hand, the role of the puta-
tive pan-cancer lncRNAs identiﬁed in this study is potentially pivotal to
cancer biology. It is interesting that their analysis suggested that well
characterized lncRNAs such as HOTAIR does not meet the stringent se-
lection criteria as a pan-cancer lncRNA, despite its frequently associa-
tion and overexpression in several cancer types such as breast cancer
(Gupta et al., 2010), liver cancer (Yang et al., 2011), and pancreatic can-
cer (Kim et al., 2013). Given the consistent expression pattern of pan-
cancer lncRNAs across cancer types, it is interesting to extrapolate the
possible roles of every one of them. Although as biomarkers, the pan-
cancer lncRNAs may not necessarily link to any driver event as
passenger genetic alterations can still demonstrate good value of
prediction. Ching et al. has shown that they may regulate critical pro-
cancerous effects such as cell proliferation and cell migration. Future
study is warranted to unveil the underlying reason for their consistency
across different cancer types. It is also of interest to understand the
difference between these pan-cancer lncRNAs with other cancer-
associated lncRNAs regarding their roles in cancer.
As pointed out by the pioneers of the pan-cancer project, there are
still limitations of analysis across cancer types in terms of inconsistent
data acquisition method, incompatible clinical data across cancerthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
8 C.H. Li, Y. Chen / EBioMedicine 7 (2016) 7–8types and false-positive discovery due to loosen statistical analysis
(Cancer Genome Atlas Research Network et al., 2013). Nonetheless, di-
versiﬁcation of cancer is still proven to be the essential strategy in
exploiting the uniqueness of every cancer types, as agreed by the
Ching et al. As such, it is possible to pick the suitable candidates out of
various targets for effective pharmaceutical intervention, as the current
technology is limiting the selection of druggable targets.
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